Former Labor Leader Shelly Yachimovich Reveals Pancreatic Cancer Battle and Chemotherapy Treatment
Shelly Yachimovich, former Knesset member and ex-chair of the Israeli Labor Party, disclosed on Sunday that she has been battling pancreatic cancer for the past eight months. She revealed in a personal social media post that the tumor was detected early without metastases, allowing for immediate surgery. Since then, she has been under close medical supervision, with encouraging CT scan results showing no signs of cancer recurrence.
Despite the positive developments, Yachimovich continues to undergo intensive chemotherapy every two weeks, describing the treatment as tough but necessary to combat the aggressive nature of pancreatic cancer. She acknowledged the difficulty of the treatment days but emphasized that she does not live in fear or despair. She maintains an active lifestyle, including cycling, going to the beach, and socializing, albeit with more caution due to treatment-related fatigue.
Yachimovich expressed deep gratitude for the support she has received from family, friends, and medical teams, particularly praising the staff at Ichilov Hospital and the Ben Yehuda Clinic of Clalit Health Services for their professionalism and dedication despite overwhelming workloads. She also reflected on the broader Israeli context, referencing the tragic events of October 7 and the heavy human toll since, which shaped her perspective on her illness.
Rejecting mystical or alternative approaches, Yachimovich stated her trust in modern medicine and remains pragmatically hopeful about recovery, while preparing for less optimistic scenarios. The post included a photo from one of her chemotherapy sessions alongside her partner of six years, whom she described as "wonderful and beloved."
The same event, reported separately by each outlet. Open a few to compare what different newsrooms emphasize — and what they leave out.
Not the same event — other stories that share this one’s people, places, or theme: background, reactions, and follow-ups.